NorthSea Therapeutics

NorthSea Therapeutics is a private, late-stage biotech advancing a platform of Structurally Engineered Fatty Acids (SEFAs) designed to overcome the limitations of natural fatty acids as drugs. Its lead assets include Icosabutate (Phase 3 for MASH), Orziloben (Phase 2 for IFALD), and SEFA-1024 (Phase 2 for severe hypertriglyceridemia). The company is positioned in large, underserved markets with a differentiated oral therapeutic approach targeting key liver and metabolic pathways.

Proprietary Structurally Engineered Fatty Acid (SEFA) platform. Chemical modifications to natural fatty acids enable targeted delivery to the liver and gut while avoiding systemic distribution and energy metabolism, allowing potent activation of receptors involved in metabolism, inflammation, and fibrosis.

In MASH, NorthSea competes with numerous biopharma companies developing diverse mechanisms (FXR agonists, ACC inhibitors, etc.), including Madrigal (approved resmetirom) and other late-stage players. In sHTG, competition includes fibrates, prescription omega-3s, and novel agents. For IFALD, the competitive field is less crowded, focusing on nutritional management and off-label use of ursodeoxycholic acid.